IPEC's New Safety Evaluation Procedure: A Q&A with IPEC Chairman Dave Schoneker - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

IPEC's New Safety Evaluation Procedure: A Q&A with IPEC Chairman Dave Schoneker
IPEC Chairman Dave Schoneker discusses current efforts toward facilitating regulatory reviews of new excipients.


Pharmaceutical Technology
Volume 32, Issue 11

PharmTech: What can you tell us about the panel of experts involved in this review program?

Schoneker: IPEC has a new excipient evaluation procedure that we put together that allows a sponsor company to have an expert panel. The panel reviews the public and private information and develops an expert report. This expert report can be either given to a drug company in support of the use of a new excipient or a higher level of use of an existing excipient, which can be provided in the NDA or it can be incorporated into a company's drug master file (DMF). If the company felt the data, for whatever reason, was confidential and they couldn't supply it to their customer, then they could put it into a DMF with a reference to the customer who could then have FDA reference that data as part of its review. There are a couple of different mechanisms. This is a system we are working through now and starting to get usage on.

To make it even more beneficial, we are very fortunate to have the help of a key toxicologist, Dr. Robert Osterberg, who directed a group at FDA's CDER that reviewed the safety of new excipients or new excipient types at the agency. Fortunately, just as we were getting ready to roll this program out, Dr. Osterburg retired and went to work for a consulting company and we asked him to coordinate these panels.

There has been a material that has already gone through this system, and FDA said it would provide us with some feedback about the kind of report that was put together so that we would have an idea about the agency's expectations. We've done that and information about that project was provided at our IPEC conference (held in October).

Online references For more information regarding IPEC's safety evaluation process, visit the following resources:
http://ipecamericas.org/newsletters/Osterberg%20New%20Excipient%20Safety%20Eval%20Procedures.pdf
http://www.ipecamericas.org/public/whatsnew.html.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here